News

Certara's Upcoming Financial Results and Conference Engagements

Certara's Upcoming Financial Results and Conference Engagements

Certara Plans to Share Financial Results Soon

Certara, Inc. (Nasdaq: CERT), a prominent global player in model-informed drug development, has exciting plans ahead. The company is scheduled to announce its financial results for both the fourth quarter and the entire year of 2024. This announcement is set to take place after the market closes on a Wednesday in late February.

Details for the Upcoming Conference Call

Management at Certara will host a conference call aimed at discussing the released financial results on that same day. Investors eager to tune in can access the conference call at 5:00 PM ET. It is recommended for attendees to ensure they register at least a day beforehand to secure their participation.

Participating in Noteworthy Investor Conferences

In addition to the financial announcement, Certara's management team will also play a role in several important investor conferences coming up in the near future. One of the primary events is the Leerink Partners Global Healthcare Conference.

Event Schedule and Details

This conference will occur on a Tuesday, featuring Certara’s participation scheduled for 1:00 PM ET. Following closely is another significant event, the Barclays 27th Annual Global Healthcare Conference.

Conference Participation

This anticipated event will take place on a Wednesday, with Certara scheduled to present at 11:30 AM ET. Both conferences provide an excellent opportunity for investors and stakeholders to gain insights directly from the company’s leadership.

Accessing Conference Webcasts

Those interested in these events will have the option to view live and archived webcasts available in the 'Investors' section of Certara's official website. This feature ensures that all interested parties can stay updated on the latest developments and insights from the company.

The Role of Certara in Drug Development

Certara stands out in the industry by enhancing the drug development process through the use of advanced biosimulation software, technology, and services. The company is dedicated to transforming traditional drug discovery and development methods. It serves a diverse clientele ranging from biopharmaceutical firms to academic institutions and regulatory bodies across the globe.

Client Base and Reach

Certara boasts a client base exceeding 2,400, which places it at the forefront of innovation in drug development practices. With a presence across 66 countries, it continues to leverage its expertise to advance medicine for better patient outcomes. Through these efforts, Certara aids in expediting the vital journey that new drugs must navigate before reaching the market.

Investor Relations and Contact Information

The Investor Relations team is always ready to assist with inquiries and provide further insights. David Deuchler of the Gilmartin Group is available for communication regarding investor relations. Reach out via email to connect and gather more specifics about Certara's initiatives and upcoming announcements.

Media Inquiries Welcome

Alyssa Horowitz is available for those seeking media-related information. An open line of communication ensures that both media representatives and investors can stay informed about Certara's latest developments.

Frequently Asked Questions

1. When will Certara release its financial results?

Certara plans to announce its financial results for the fourth quarter and full year of 2024 on February 26, 2025, after the market closes.

2. How can I listen to the financial conference call?

Investors can listen to the financial conference call by registering online in advance. It's suggested to register at least one day before.

3. What investor conferences will Certara participate in?

Certara will participate in the Leerink Partners Global Healthcare Conference and the Barclays 27th Annual Global Healthcare Conference in March.

4. Where can I find more information about these webcasts?

Live and archived webcasts for the conferences will be available in the “Investors” section of Certara's official website.

5. How does Certara contribute to drug development?

Certara uses biosimulation software and services to transform traditional drug discovery and development processes, helping accelerate the delivery of new medicines.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 2

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 4

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 2

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 2

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading

Top 5 Most Recently Viewed Articles

Sprott Focus Trust Reports Quarterly Distribution and Insights

Updated Category News Views 195

Sprott Focus Trust Announces Quarterly Share Distribution In an uplifting update for investors, Sprott Focus Trust, Inc. (Nasdaq: FUND) has just declared a quarterly distribution of $0.1274 per share on its Common Stock. This distribution offers shareholders a choice between receiving payment in additional shares or cash. Set for disbursement on September 29, 2025,...

Continue Reading
Personal Injury Lawsuits: What You Need to Know Before Filing

Updated Category Personal Finance Views 1165

If you have been injured due to someone else's negligence or careless actions, you may be considering filing a personal injury lawsuit. Consulting a personal injury claim lawyer can help you understand your rights and the complexities involved in pursuing compensation. Personal injury lawsuits can be an effective way to recover damages for medical bills, lost wages, pain...

Continue Reading
Honeywell and Qualcomm Join Forces to Advance AI in Energy Sector

Updated Category News Views 188

Collaborating to Enhance AI Solutions in Energy Honeywell (NASDAQ: HON) and Qualcomm (NASDAQ: QCOM) Technologies, Inc. are making headlines with their groundbreaking collaboration aimed at revolutionizing artificial intelligence (AI) solutions within the energy sector. This partnership is a significant step towards enhancing Honeywell's automation offerings by seamlessly...

Continue Reading
Celebrating Diversity: The Best Gift for Foodies This Season

Updated Category News Views 106

Celebrating the Best Gift for Foodies Packed with Purpose (PwP), a Certified Woman-Owned and B Corp gifting company, has made headlines with its Black-Owned Spotlight Gift Basket, recently awarded as the Best Gift for Foodies. Understanding the Award Recognition This prestigious recognition comes from the USA Today 10Best Readers' Choice Awards, where a dedicated panel of...

Continue Reading
Coloplast A/S Updates Organic Growth and EBIT Margin Guidance

Updated Category News Views 620

Coloplast A/S Adjusts Financial Guidance for FY 2024/25 Coloplast A/S has revised its financial expectations for FY 2024/25, particularly in terms of organic growth and EBIT margin before special items. The anticipated organic growth has been adjusted to approximately 7%, down from the previous expectation of 8-9%. Additionally, the EBIT margin is now projected to be in...

Continue Reading